Aldeyra Therapeutics Inc. (NASDAQ:ALDX)‘s stock had its “buy” rating reissued by equities research analysts at HC Wainwright in a research report issued to clients and investors on Friday.

A number of other equities analysts also recently issued reports on ALDX. Zacks Investment Research raised shares of Aldeyra Therapeutics from a “hold” rating to a “buy” rating and set a $7.50 price target for the company in a research note on Tuesday, October 25th. Cowen and Company reissued a “buy” rating on shares of Aldeyra Therapeutics in a research note on Tuesday, November 15th. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus target price of $14.30.

Aldeyra Therapeutics (NASDAQ:ALDX) opened at 6.30 on Friday. Aldeyra Therapeutics has a 52 week low of $3.39 and a 52 week high of $8.19. The stock’s market cap is $39.34 million. The stock has a 50 day moving average price of $6.45 and a 200-day moving average price of $6.04.

Aldeyra Therapeutics (NASDAQ:ALDX) last posted its earnings results on Monday, November 14th. The biotechnology company reported ($0.38) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.39) by $0.01. On average, equities analysts anticipate that Aldeyra Therapeutics will post ($1.69) EPS for the current fiscal year.

Institutional investors have recently made changes to their positions in the stock. AWM Investment Company Inc. acquired a new position in shares of Aldeyra Therapeutics during the second quarter worth $5,222,000. Vanguard Group Inc. increased its position in shares of Aldeyra Therapeutics by 3.1% in the second quarter. Vanguard Group Inc. now owns 125,125 shares of the biotechnology company’s stock worth $712,000 after buying an additional 3,718 shares in the last quarter. BlackRock Fund Advisors increased its position in shares of Aldeyra Therapeutics by 1,944.6% in the second quarter. BlackRock Fund Advisors now owns 20,630 shares of the biotechnology company’s stock worth $117,000 after buying an additional 19,621 shares in the last quarter. FMR LLC increased its position in shares of Aldeyra Therapeutics by 25.0% in the second quarter. FMR LLC now owns 1,797,811 shares of the biotechnology company’s stock worth $10,230,000 after buying an additional 360,000 shares in the last quarter. Finally, Perceptive Advisors LLC increased its position in shares of Aldeyra Therapeutics by 56.4% in the second quarter. Perceptive Advisors LLC now owns 1,940,458 shares of the biotechnology company’s stock worth $11,041,000 after buying an additional 700,000 shares in the last quarter. 50.82% of the stock is owned by institutional investors and hedge funds.

About Aldeyra Therapeutics

Aldeyra Therapeutics, Inc, formerly Aldexa Therapeutics, Inc, is a biotechnology company. The Company’s principal activities include raising capital and research and development activities. The Company’s segment is the identification and development of a treatment for diseases related to high levels of aldehydes.

5 Day Chart for NASDAQ:ALDX

Receive News & Stock Ratings for Aldeyra Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aldeyra Therapeutics Inc. and related stocks with our FREE daily email newsletter.